Boston Partners
ARCT icon

Boston Partners’s Arcturus Therapeutics ARCT Stock Holding History

Boston Partners’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-17,169
Closed -$580K – 710
2024
Q1 		$580K Buy
+17,169
New +$608K ﹤0.01% 672

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Boston Partners's ARCT Position: Q2 2024 in Review

Boston Partners sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 17,169 shares — an estimated $580K sold.

Boston Partners first reported a position in ARCT in Q1 2024 and held it in 1 quarter. The position peaked at $580K in Q1 2024. 171 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Boston Partners reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Boston Partners sold 17,169 Arcturus Therapeutics shares in Q2 2024, an estimated $580K.
  • Boston Partners first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 1 quarter.
  • Boston Partners's Arcturus Therapeutics position peaked at $580K in Q1 2024.
  • 171 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Boston Partners's 13F filing for Q2 2024, filed 14 Aug 2024.